11 September 2026
11 September 2026
Biotechs and investors are increasingly altering their strategies amid changes in the development and commercial landscape.
Proceeds will go towards a pivotal trial of the candidate in paediatric patients.
Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201.
The site will produce bioprocess equipment and consumables used in developing biologics and vaccines.
Thoracic oncologists previously touted Hyrnuo’s potential in HER2-mutant NSCLC in both the first- and second-line settings.
The healthcare team dive into the latest data and emerging trends from the ESC Congress and ERS Congress.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
